Literature DB >> 7591545

Rational prescribing and interpractitioner variation. A multilevel approach.

P Davis1, B Gribben.   

Abstract

There are marked geographical variations in rates of medical and surgical intervention at every level of aggregation and in every aspect of medical practice. These data raise a range of important theoretical, methodological, and policy issues. Much the same pattern of variation characterizes the prescription and consumption of therapeutic drugs. Data from a survey of general practice in New Zealand confirm the existence of extensive variability in prescribing. Multilevel techniques are deployed to isolate the specific interpractitioner element in this variability. Controlling for patient, diagnostic, and practitioner variables improves the predictive power of the model but does not reduce the extent of interpractitioner variability in prescribing rates. The existence of such variability raises questions about the role of clinical uncertainty and professional autonomy in the promotion of rational therapeutics in medical practice.

Entities:  

Mesh:

Year:  1995        PMID: 7591545     DOI: 10.1017/s0266462300008655

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  12 in total

1.  Whom should we profile? Examining diabetes care practice variation among primary care providers, provider groups, and health care facilities.

Authors:  Sarah L Krein; Timothy P Hofer; Eve A Kerr; Rodney A Hayward
Journal:  Health Serv Res       Date:  2002-10       Impact factor: 3.402

2.  Understanding adherence to official guidelines on statin prescribing in primary health care--a multi-level methodological approach.

Authors:  H Ohlsson; U Lindblad; T Lithman; B Ericsson; U-G Gerdtham; A Melander; L Råstam; J Merlo
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

3.  General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.

Authors:  Torben Dybdahl; Morten Andersen; Jakob Kragstrup; Ivar Sønbø Kristiansen; Jens Søndergaard
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

4.  Development of NSAIDs prescription indicators based on health outcomes.

Authors:  Rocío Fernández Urrusuno; Miguel Pedregal González; Ma Amparo Torrecilla Rojas
Journal:  Eur J Clin Pharmacol       Date:  2007-10-31       Impact factor: 2.953

5.  Access to new medications to treat schizophrenia.

Authors:  Tami L Mark; Riad Dirani; Eric Slade; Patricia A Russo
Journal:  J Behav Health Serv Res       Date:  2002-02       Impact factor: 1.505

6.  Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction.

Authors:  S R Majumdar; T S Inui; J H Gurwitz; M W Gillman; T J McLaughlin; S B Soumerai
Journal:  J Gen Intern Med       Date:  2001-06       Impact factor: 5.128

7.  Antibiotic prescribing patterns and hospital admissions with respiratory and urinary tract infections.

Authors:  Rocío Fernández Urrusuno; Miguel Pedregal González; Ma Amparo Torrecilla Rojas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

8.  Therapeutic traditions, patient socioeconomic characteristics and physicians' early new drug prescribing--a multilevel analysis of rosuvastatin prescription in south Sweden.

Authors:  Henrik Ohlsson; Basile Chaix; Juan Merlo
Journal:  Eur J Clin Pharmacol       Date:  2008-10-04       Impact factor: 2.953

9.  Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription--a multilevel methodological approach.

Authors:  Henrik Ohlsson; Juan Merlo
Journal:  BMC Health Serv Res       Date:  2007-05-08       Impact factor: 2.655

10.  Bad apples or spoiled barrels? Multilevel modelling analysis of variation in high-risk prescribing in Scotland between general practitioners and between the practices they work in.

Authors:  Bruce Guthrie; Peter T Donnan; Douglas J Murphy; Boikanyo Makubate; Tobias Dreischulte
Journal:  BMJ Open       Date:  2015-11-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.